Abstract
BACKGROUND: Microsecretory adenocarcinoma (MSA) is a newly identified entity in the WHO classification of salivary gland tumors characterized by MEF2C::SS18 fusion. It was previously considered as adenocarcinoma not otherwise specified (NOS). With the discovery of new gene fusions specifying distinct salivary gland tumors and restricting the diagnosis of adenocarcinoma NOS, five cases of MSA were recognized for the first time using targeted RNA sequencing. Afterwards, further authors reported MSA in the salivary glands and more recently in the skin. METHODS: We reviewed the literature for all cases of MSA reported in English-language articles. We comprehensively discussed clinical, histopathological, immunohistochemical and molecular findings of the retrieved cases. RESULTS: Forty cases were identified. Thirty cases occurred in the salivary glands and ten cases occurred in the skin. They were characterized histologically by a well circumscribed mass formed of microcysts containing basophilic secretions and enclosed in a fibromyxoid stroma. The tumor cells were flattened resembling intercalated duct cells with minimal eosinophilic cytoplasm and small oval nuclei. By immunohistochemistry, the tumor cells were positive for SOX10, S100, p63 and negative for p40, calponin and mammaglobin. However, cutaneous cases had a somewhat different immunoprofile. CONCLUSION: MSA is a salivary gland malignancy that also has a cutaneous counterpart. Focusing on emphasising the almost consistent histopathological and immunohistochemical findings help in increasing the awareness of clinicians, surgeons and pathologists about it and at the same time lessening the need for more complicated diagnostic methods that are not readily available in all institutions. Despite the low-grade nature of this tumor, thorough management and rigorous follow up of cases are highly recommended due to occasional aggressive behaviour.